259 related articles for article (PubMed ID: 29260291)
1. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
van den Berg P; van Haard PMM; van der Veer E; Geusens PP; van den Bergh JP; Schweitzer DH
Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
[TBL] [Abstract][Full Text] [Related]
2. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
3. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
4. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
7. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
9. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
[TBL] [Abstract][Full Text] [Related]
10. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.
Eekman DA; Bultink IE; Heijboer AC; Dijkmans BA; Lems WF
BMC Musculoskelet Disord; 2011 Jul; 12():167. PubMed ID: 21774839
[TBL] [Abstract][Full Text] [Related]
13. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
[TBL] [Abstract][Full Text] [Related]
14. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
16. Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study.
Senay A; Fernandes JC; Delisle J; Morin SN; Perreault S
Arch Osteoporos; 2019 Aug; 14(1):87. PubMed ID: 31375983
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
18. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
19. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
20. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]